Google and Meta treat research peptides as a suspension risk. We build the store, run the Search, Shopping and Meta campaigns, and engineer every page to survive review — so your ad accounts keep spending while your competitors get shut off.
Peptides sit in the healthcare and unapproved-substances category. The platforms don't slow-walk it — a violation can suspend the account on detection, and the domain can be flagged so even a fresh account on the same URL won't run. This is the wall most sellers hit.
Benefit language on a product page, a before/after in an ad, a dosage in the copy — flagged, disapproved, then account-level suspension. Spend stops overnight.
Research-use framing sitewide, COAs attached, no medical claims anywhere the crawler looks. Ads pass review, stay on, and the curve keeps climbing week over week.
BPC-157, TB-500, Ipamorelin, CJC-1295 and similar are read as unapproved substances. Marketed for human use, they trigger policy conflict instantly.
Not just product pages — blog posts, meta descriptions, image alt text and testimonials. One stray "heals" or "boosts recovery" is enough.
Repeat violations suspend the account; the domain gets flagged. Reinstatement runs weeks to months and isn't guaranteed. It's a revenue emergency.
Toggle your current setup. The meter reads the same signals a platform reviewer does. Most sellers start deep in the red — and don't know it until the ads stop.
Risk index / 100
—
A peptide only works when its residues are bonded in the right order. Same with growth in this niche — the store, the search demand, the social demand, and the compliance layer only perform when they're built as one connected sequence. We run all four.
Shopify or WordPress, engineered for review from the first line of markup: research-use framing baked into every template, COA display on the PDP, clean policy pages, and no claim language hiding in alt text or meta tags.
Buyer-intent keywords over educational ones, Merchant Center feeds structured to pass, research-use ad copy, and a weekly review cadence with a 24-hour response the moment anything is disapproved. We keep the account eligible, then we scale it.
Creative and landing experiences written to clear Meta's stricter review, an approved-compound-first strategy, pixel and CAPI tracking done properly, and retargeting that fills the funnel your search demand opens — without tripping the health-claim tripwires.
The bond that holds the other three together. Sitewide health-claim scrubbing, COA management, LegitScript and merchant-vetting guidance, and continuous policy monitoring so a platform update doesn't quietly turn your account off next quarter.
When the account never goes dark, spend compounds instead of resetting. Here's the shape of a research-peptide account before and after a compliance-first rebuild.
Viewing account before compliance rebuild
Every SKU we ship reads as research-grade: compound name, third-party purity, COA on the page, and a research-use tag that never contradicts the marketing. This is the exact presentation that keeps the catalog eligible.
↑ Reference renders of the compliant PDP layout we build. Swap in your own catalog, photography and live COAs.
This part is a real sequence, so the order matters. We stabilise the account first, then we let it grow — never the other way around.
We crawl the whole site the way a reviewer does — product pages, blog, alt text, meta descriptions, checkout — and map every claim, gap and disapproval risk before a cent of new spend goes out.
Days 1–5Research-use framing applied sitewide, COAs wired into every PDP, policy pages rewritten, feeds restructured, tracking rebuilt on GA4 with server-side events. The store becomes reviewable end to end.
Weeks 1–3Search, Shopping and Meta go live with review-safe creative and buyer-intent targeting. We stage the ramp so bidding history builds without tripping a spend-velocity flag.
Weeks 3–5Weekly policy review, 24-hour response on any disapproval, and continuous scaling into the channels that convert. You get one dashboard and a report that reads in two minutes.
OngoingFigures describe our operating standard and representative modelling — not guaranteed platform outcomes.